Domestic Firm Joins Competitive Market for Anti-Hypertension Treatments

Published: 2005-01-20 06:58:00

Updated: 2005-01-20 06:58:00

The pharmaceutical industry expects an elevated level of competition in the domestic ARB (angiotensin II receptor blocker) hypertension treatment market currently predominated by foreign-invested firms, with an introduction of Olmetec (olmesartan medoxomil) by Daewoong Pharmaceutical.

Discovered and developed by Sankyo Co. Ltd., one of Japan's leading pharmaceutical firms, the launching of ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.